Adipokine imbalance and its role in the pathogenesis of novel coronavirus infection-Reference-Cited by-同舟云学术

Adipokine imbalance and its role in the pathogenesis of novel coronavirus infection

Published:2024-01-24 Issue:4 Volume:22 Page:164-173
ISSN:1819-3684
Container-title:Bulletin of Siberian Medicine
language:
Short-container-title:Bûll. sib. med.

Author:

Bespalova I. D.¹^ORCID,Mitrichenko U. M.¹^ORCID,Kalyuzhin V. V.¹^ORCID,Koroleva E. S.¹^ORCID,Koshchavtseva Yu. I.¹^ORCID,Romanov D. S.¹^ORCID,Pershina D. E.¹^ORCID

Affiliation:

1. Siberian State Medical University

Abstract

The review summarizes and analyzes the results of major foreign studies on the role of adipokine imbalance in the development of a severe course and complications of novel coronavirus infection (COVID-19). Adipokines are biologically active compounds produced by adipose tissue cells and involved in the regulation of metabolism and the functioning of the immune system. Obesity is a proven risk factor for severe COVID-19 due to high hormonal and metabolic activity of visceral adipose tissue. A deep understanding of COVID-19 pathogenesis from the point of view of the role of adipokine imbalance in it can provide the grounds for the development of effective pathogenetic approaches to the prevention of a severe course and complications of novel coronavirus infection.

Publisher

Siberian State Medical University

Reference83 articles.

1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. et al. Novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;82(8):727–733. DOI: 10.1056/NEJMoa2001017.

2. Goroshko N.V., Patsala S.V., Emel'yanova E.K. Smertnost' trudosposobnogo naseleniya Rossii v usloviyakh pandemii COVID-19. Sotsial'nye aspekty zdorov'ya naseleniya. 2022;68(5):1. DOI: 10.21045/2071-5021-2022-68-5-1.

3. Kashtanova E.V., Shakhtshneider E.V., Kruchinina M.V., Logvinenko I.I., Stryukova E.V., Ragino Yu.I. Biokhimicheskie, molekulyarno-geneticheskie i klinicheskie aspekty COVID-2019. Byulleten' sibirskoi meditsiny. 2021;20(1):147–157. DOI: 10.20538/1682-0363-2021-1-147-157.

4. Trougakos I.P., Stamatelopoulos K., Terpos E., Tsitsilonis O.E., Aivalioti E., Paraskevis D. et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J. Biomed. Sci. 2021;28(1):9. DOI: 10.1186/s12929-020-00703-5.

5. Bespalova I.D., Bychkov V.A., Kalyuzhin V.V., Ryazantseva N.V., Medyantsev Yu.A., Osikhov I.A. i dr. Kachestvo zhizni bol'nykh gipertonicheskoi bolezn'yu s metabolicheskim sindromom: vzaimosvyaz' s markerami sistemnogo vospaleniya. Byulleten' sibirskoi meditsiny. 2013;12(6):5–11. DOI: 10.20538/1682-0363-2013-6-5-11.